行情

OASMY

OASMY

Oasmia Pharm
OTCMKTS

实时行情|Nasdaq Last Sale

1.175
+0.125
+11.90%
已收盘, 16:00 11/21 EST
开盘
1.175
昨收
1.050
最高
1.175
最低
1.175
成交量
122
成交额
140
52周最高
4.800
52周最低
0.9381
市值
4.03亿
市盈率(TTM)
-14.3643
分时
5日
1月
3月
1年
5年

OASMY 新闻

  • LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Oasmia Pharmaceutical AB to Contact the Firm
  • Newsfile.09/04 15:30
  • 俄总统新闻秘书:重返八国集团不是俄方目标
  • 央视.08/22 22:43
  • 网易考拉易主? 丁磊“再造一个网易”梦碎
  • 投资者网.08/22 22:40
  • 美联储9月降息板上钉钉?纽交所交易员:多此一举
  • 一财网.08/22 22:32

更多

所属板块

制药
+0.60%
制药与医学研究
+0.43%

热门股票

名称
价格
涨跌幅

OASMY 简况

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. Its drugs portfolio comprises six candidates: Paclical, Doxophos, Docecal and OAS-19, which are implemented in human treatment, as well as Paccal Vet-CA1 and Doxophos Vet, introduced in cancer in dogs. The Company’s medicines are based on the patented XR-17 excipient, which forms micelles with water-soluble substances. Furthermore, It cooperates with Abbott Laboratories, Pharmasyntez, Nippon Zenyaku Kogyo and Medison Pharma. The Company is a parent of Oasmia Global Supplies AB and Oasmia Animal Health AB.
展开

Webull提供Oasmia Pharmaceutical AB的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。